Primary melanoma of the stomach treated by BRAF inhibitor and immunotherapy

Dig Liver Dis. 2016 Aug;48(8):974. doi: 10.1016/j.dld.2016.04.002. Epub 2016 Apr 12.

Authors

Elena Bolzacchini¹, Ilaria Marcon², Giordano Bernasconi³, Graziella Pinotti²

Affiliations

¹ U.O. Oncologia Medica, Ospedale di Circolo e Fondazione Macchi, Azienda Socio Sanitaria dei Sette Laghi, Varese, Italy. Electronic address: elena.bolzacchini@hotmail.it.
² U.O. Oncologia Medica, Ospedale di Circolo e Fondazione Macchi, Azienda Socio Sanitaria dei Sette Laghi, Varese, Italy.
³ U.O. Medicina ad indirizzo Gastroenterologico, Presidio ospedaliero di Busto Arsizio, Azienda Socio Sanitaria territoriale ASST della Valle Olona, Busto Arsizio, Italy.

PMID: 27158123
DOI: 10.1016/j.dld.2016.04.002

No abstract available

Publication types

Case Reports

MeSH terms

Aged
Antibodies, Monoclonal / therapeutic use
Endoscopy, Digestive System
Enzyme Inhibitors / therapeutic use*
Fatal Outcome
Humans
Immunotherapy / methods*
Indoles / therapeutic use
Ipilimumab
Magnetic Resonance Imaging
Male
Melanoma / diagnostic imaging
Melanoma / drug therapy*
Mutation
Proto-Oncogene Proteins B-raf / antagonists & inhibitors*
Proto-Oncogene Proteins B-raf / genetics
Stomach Neoplasms / diagnostic imaging
Stomach Neoplasms / drug therapy*
Sulfonamides / therapeutic use
Tomography, X-Ray Computed
Vemurafenib

Substances

Antibodies, Monoclonal
Enzyme Inhibitors
Indoles
Ipilimumab
Sulfonamides
Vemurafenib
BRAF protein, human
Proto-Oncogene Proteins B-raf